James Rushworth
Senior Scientist II, Sixfold Bioscience
Dr James Rushworth is a Senior Scientist and Intellectual Property Manager at Sixfold Bioscience, a venture-backed preclinical-stage biotech that utilises advanced nanoengineering to create safer and more targeted systems for the delivery of RNA therapies.
As a chemist by training, James forms part of the R&D team that drives Sixfold’s innovation. He actively contributes to the development of Sixfold’s proprietary platform, Mergo, and is also tasked with determining the most effective methods of protecting the platform through management of the company’s patent portfolio.
James holds a PhD in Chemistry from Imperial College London, where he worked on polymeric drug delivery (at the Commonwealth Scientific & Industrial Research Organisation, CSIRO, Melbourne) and the development of novel tubulin inhibitors for cancer therapy (at Imperial College).
